OZM Price sensitive 30 Jan 2026, 4:11 PM

Quarterly Activities/Appendix 5B Cash Flow Report

Ozaurum Resources Ltd

Quarterly Activities/Appendix 5B Cash Flow Report

Key points

  • High-grade gold intercepts strengthen resource expansion case at Mulgabbie
  • Heap-leach amenability confirmed with exceptional percolation rates
  • Preliminary column leach testwork indicates >60% gold recovery within 7 days

Full summary

OzAurum Resources Ltd (ASX: OZM) has provided a summary of its activities for the December 2025 quarter, highlighting continued positive steps in the progress of the feasibility study supporting a low-cost, scalable heap-leach operation at the Mulgabbie North Gold Project. Key highlights include high-grade gold intercepts from RC and diamond drilling that strengthen the resource expansion case, confirmation of heap-leach amenability through exceptional percolation rates, and preliminary column leach testwork indicating over 60% gold recovery within 7 days. The company has also lodged the Mining Development & Closure Proposal for the Stage 1 Small Mining Operation under the expedited approval pathway, and secured the Heap Leach Agglomeration Process Plant required to support the Stage 1 Mulgabbie North Gold Project. Drilling continued at the James, Ben, and Cross Fault prospects, returning further high-grade results. The company is progressing a staged heap leach development strategy at Mulgabbie North, designed to deliver early gold production and self-funded growth.

Guidance

The company expects to report final recoveries from the column leach test in 4-5 weeks' time. The Competent Person cautions that the metallurgical results are preliminary and subject to further analysis.

Outlook

OzAurum's focus remains on fast-tracking Mulgabbie North toward development and maximizing long-term value for shareholders, with the company's staged heap leach development strategy designed to deliver early gold production and self-funded growth.

Summary generated by a large language model. Please interpret with care.

Sign in for more about this company, including guidance changes and other insights.
Sign in